Preimplantation genetic screening (PGS), also known as preimplantation genetic testing for aneuploidy (PGT-A), determines the chromosomal status of an embryo by screening all 23 chromosome pairs, providing valuable insights to researchers studying IVF.
IVF failure can sometimes be due to embryo aneuploidy - embryos with an abnormal number of chromosomes.1,2 Aneuploidy can occur in any embryo; however, the chances increase with maternal age.3,4
Preimplantation genetic screening was originally performed using fluorescence in situ hybridization (FISH). Because FISH does not screen all 24 chromosomes, its efficacy and accuracy for detecting euploid embryos is limited.
New technologies were developed and applied to PGS. Array-based technology facilitated screening of all 24 chromosomes in the embryo, significantly improving PGS.
NGS, the latest technological breakthrough, is setting a new standard in PGS. NGS offers reliable PGS results, streamlined workflows, higher throughput capabilities, and customizable assays for easy portfolio expansion.
Following ovarian stimulation and egg retrieval, a single or a few cells are biopsied from the in vitro embryo.
In vitro embryos are screened for aneuploidy.
After fertilized oocytes are retrieved, a single or few cells are removed from the in vitro embryo through a biopsy. The cell or cells are analyzed for their aneuploidy status by screening all 24 chromosomes.
Preimplantation genetic screening can be performed using next-generation sequencing, the latest technological innovation, or an array-based method.
Dr. Nathan Treff discusses the technology behind preimplantation genetic screening.Listen to Podcast
Empower your research with these NGS-based preimplantation genetic screening products. Get an entire view of chromosomal status.
The VeriSeq PGS Kit takes advantage of next-generation sequencing technology to provide comprehensive, accurate screening of all 24 chromosomes. NGS offers the opportunity for improved assay workflow, higher throughput, and enhanced performance over array-based PGS.1
Perform rapid aneuploidy screening using the MiSeq System. Multiplex up to 24 samples per run. The on-instrument software performs secondary analysis of the sequencing data, demultiplexing and aligning the reads to the reference genome. BAM files from the MiSeq System are imported directly into the BlueFuse Multi Analysis Software using the prepared sample sheet.
BlueFuse software provides molecular cytogenetic and genetic information obtained from the biopsied in vitro embryos, analyzed in a single framework. It offers a clear, intuitive user interface, a common workflow, and scales for the needs of your lab. This widely-implemented software is used in the majority of laboratories performing PGS.
This technique is used to assess the likelihood of an embryo carrying a gene mutation that may be linked to an inherited genetic disorder.
Together, NGS and microarrays enable cytogenomic analysis of chromosome aberrations for constitutional and cancer research.